13F Holdings
中文EN

NVCR NovoCure Ltd

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1645113 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.9%
TTM net income YoY31.5%
TTM EPS YoY34.2%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin-17.2%
Net margin-16.8%
FCF margin-3.4%
EBITDA margin-14.8%

Returns

ROE-35.2%
ROA-11.1%
ROIC (approx.)-77.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets57.7%
Debt / equity0.00x
Current ratio2.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.01x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$655.35M$605.22M$509.34M$537.84M$535.03M
Cost of revenue$166.88M$137.18M$128.28M$114.87M$114.88M
Gross profit$488.47M$468.04M$381.06M$422.97M$420.15M
R&D expense$224.54M$209.65M$223.06M$206.09M$201.30M
SG&A expense$177.67M$189.83M$164.06M$132.75M$126.13M
Operating income-$153.80M-$170.50M-$232.87M-$89.52M-$44.33M
Interest expense$22.22M$11.66M$4.91M$8.11M$8.84M
Pretax income-$136.25M-$131.16M-$191.74M-$81.85M-$52.08M
Income tax-$23,000$37.47M$15.30M$10.69M$6.28M
Net income-$136.23M-$168.63M-$207.04M-$92.53M-$58.35M
EBITDA-$139.15M-$159.26M-$221.90M-$78.90M-$34.08M
EPS (basic)-1.22-1.56-1.95-0.88-0.56
EPS (diluted)-1.22-1.56-1.95-0.88-0.56
Weighted avg. shares (diluted)111.47M107.83M106.39M104.66M103.43M
Balance sheet
Cash & equivalents$93.55M$166.09M$240.82M$115.83M$209.61M
Receivables$89.44M$74.23M$61.22M$86.26M$93.57M
Inventory$41.11M$35.09M$38.15M$29.38M$24.43M
Current assets$646.73M$1.11B$1.03B$1.11B$1.07B
PP&E, net$77.61M$77.66M$51.48M$32.68M$22.69M
Total assets$804.33M$1.24B$1.15B$1.19B$1.14B
Current liabilities$223.23M$756.39M$179.12M$158.78M$142.60M
Short-term debt$0————
Long-term debt$195.05M$97.30M$568.82M$565.51M$562.22M
Total debt$195.05M$97.30M$568.82M$565.51M$562.22M
Total liabilities$463.86M$880.61M$783.63M$750.48M$729.00M
Shareholders' equity$340.47M$360.18M$362.50M$441.17M$410.49M
Net debt$101.50M-$68.79M$328.00M$449.68M$352.61M
Shares outstanding112.49M108.52M107.08M105.05M103.97M
Cash flow statement
Operating cash flow-$49.03M-$26.37M-$73.34M$30.79M$82.76M
Capital expenditure$26.65M$42.85M$27.09M$21.36M$24.17M
Free cash flow-$75.68M-$69.22M-$100.43M$9.43M$58.59M
Investing cash flow$437.28M-$140.24M$184.15M-$139.96M-$144.83M
Financing cash flow-$451.34M$90.31M$15.79M$15.49M$25.70M
Depreciation & amortization$14.65M$11.23M$10.97M$10.62M$10.25M
Stock-based compensation$104.83M$160.03M$115.61M$106.95M$94.90M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.